Realizing the Potential of PCSK9 Inhibition: A Novel Oral Macrocyclic Peptide on the Horizon

M John Chapman; Chris J Packard

doi:10.1016/j.jacc.2023.03.384

Realizing the Potential of PCSK9 Inhibition: A Novel Oral Macrocyclic Peptide on the Horizon

J Am Coll Cardiol. 2023 Apr 25;81(16):1565-1568. doi: 10.1016/j.jacc.2023.03.384.

Authors

M John Chapman¹, Chris J Packard²

Affiliations

¹ Faculty of Medicine, Sorbonne University, Paris, France; Cardiovascular Disease Prevention Unit, Pitié-Salpetrière University Hospital, Paris, France; National Institute for Health and Medical Research (INSERM), Paris, France. Electronic address: john.chapman@upmc.fr.
² Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.

PMID: 37076210
DOI: 10.1016/j.jacc.2023.03.384

No abstract available

Keywords: LDL cholesterol; PCSK9; atherosclerotic cardiovascular disease; lipoprotein(a); oral macrocyclic PCSK9 inhibitor; remnant lipoproteins; triglyceride-rich lipoproteins.

Publication types

Editorial
Comment

MeSH terms

Humans
Lipoproteins*
Proprotein Convertase 9*
Triglycerides

Substances

PCSK9 protein, human
Proprotein Convertase 9
Lipoproteins
Triglycerides